Please read this first. Everything below is background, not guidance for your child. These are powerful prescription medicines for moderate-to-severe disease, decided on a case-by-case basis by a specialist who weighs your child's severity, history, and risks — and monitors them over time. Nothing here should be started, stopped, requested, or ruled out based on a web page. The goal is only to make the doctor's conversation less bewildering.
First: most children never need this
It's worth saying plainly, because the topic can be scary. The large majority of childhood eczema is controlled with good skin care and topical treatment. Systemic (whole-body) medicines are reserved for moderate-to-severe eczema that hasn't responded to those measures — and even then, it's a considered step, not a first move. If your child is doing okay on creams, this guide is just for understanding.
The two newer families
Biologics (targeted injected antibodies)
Biologics are lab-made antibodies given by injection that target specific parts of the immune signaling behind eczema, rather than broadly suppressing the immune system. Dupilumab was the first approved for children and is now used down into younger ages; tralokinumab is another. In studies they meaningfully reduced severity, and they're generally regarded as having a well-established safety profile, with side effects that are usually mild-to-moderate (conjunctivitis — eye irritation — is a known one). They don't require the same routine blood monitoring some other systemic drugs do.
JAK inhibitors (targeted oral pills)
JAK inhibitors (such as abrocitinib and upadacitinib) are pills taken by mouth that block a different set of inflammatory signals. In trials they often worked fast and strongly, especially for itch. The trade-off: they carry a broader range of possible side effects and require careful safety monitoring by the prescriber (including blood tests), which is exactly why they're a specialist decision. "Faster and stronger" and "needs closer watching" travel together here.
The 2024 dermatology guidelines recognize both families as options for moderate-to-severe disease, and stress that the choice should be individualized — based on severity, the child's and family's preferences, and the risk profile. There's no universal "best"; there's the right fit for a particular child, chosen with a specialist.
What this means for you as a parent
- If creams are working, breathe easy — you likely never need this chapter.
- If they're not, a referral to a dermatologist is the door, not the internet. Only a specialist can judge severity and suitability.
- Come informed, not decided. Knowing that "biologics = targeted injections, generally reassuring safety" and "JAK inhibitors = fast oral pills that need monitoring" lets you follow the conversation and ask good questions — without arriving with a demand.
- Ask about the whole picture: how well controlled things are now, whether stepping up is warranted, the benefits and risks of each option for your child, and what monitoring looks like.
A note on hope and honesty
For families worn down by years of severe, sleep-stealing eczema, these newer treatments have genuinely changed lives — real, meaningful relief where creams had failed. That hope is honest. So is the caution: they're serious medicines with real considerations, chosen carefully and watched closely. Both things are true, and a good dermatologist will hold both with you.
Walk in with the full picture of your child's eczema
If you're heading toward a specialist conversation, the clearest thing you can bring is an honest record: how severe it's really been, how much sleep it's costing, what you've already tried. Ollowen turns your daily check-ins into exactly that.
Opening soonFree for 14 days · no card, no account · your child's data stays on your device
Sources
- Systematic review. Systemic Therapies for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents.
- Systemic Therapy for Atopic Dermatitis: Choosing Biologics or JAK Inhibitors for Children and Adults. J Allergy Clin Immunol: In Practice.
- Annals of Allergy, Asthma & Immunology. New treatments in atopic dermatitis: an update.
More Ollowen guides: see all →